Clinical Pharmacokinetic Considerations in Gastroenterology

  • Varocha Mahachai
Part of the Topics in Gastroenterology book series (TGEN)

Abstract

Physiological changes in gastrointestinal and liver disease alter drug pharmacokinetics, although the alterations are of poorly defined clinical significance. Quite often these changes are unpredictable, depending on the nature of the drug and the clinical status of the patient. In the presence of liver disease, the dosage of a drug metabolized by the liver is often adjusted empirically. Specific guidelines are lacking because the available clinical and biochemical assessments of liver disease are inadequate. Even less is known about the effect of gastrointestinal disease on drug handling. Impaired drug absorption may become critical when a rapid onset of drug action is required or when elimination is so rapid that effective plasma concentrations cannot be maintained. Therefore, the adjustment of dosage and route of administration for some drugs may be necessary to attain optimal pharmacological effect.

Keywords

Liver Disease Drug Absorption Celiac Disease Gastric Emptying Hepatic Blood Flow 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Cooke AR, Hunt JN. Absorption of acetylsalicylic acid from unbuffered and buffered gastric contents. Am J Dig Dis 1970;15:95–102.PubMedCrossRefGoogle Scholar
  2. 2.
    Cooke AR, Birchall A. Absorption of ethanol from the stomach. Gastroenterology 1969;57:269–272.PubMedGoogle Scholar
  3. 3.
    Levine RR. Factors affecting gastrointestinal absorption of drugs. Am J Dig Dis 1970;15:171–188.PubMedCrossRefGoogle Scholar
  4. 4.
    Wass M, Evered DF. Transport of penicillamine across the mucosa of the rat small intestine in vitro. Biochem Pharmacol 1970;19:1287–1295.PubMedCrossRefGoogle Scholar
  5. 5.
    Schanker LS. On the mechanism of absorption of drugs from the gastrointestinal tract. J Med Pharm Chem 1960;2:343–359.PubMedCrossRefGoogle Scholar
  6. 6.
    Winne D. The influence of unstirred layers on intestinal absorption. In: Intestinal Permeation: Proceedings of the Fourth Workshop Conference, Vol. 4 (Krumer K, Lauterbach F, eds). Hoechst, Schloss Reisenburg, October 1975, pp. 19–22. Amsterdam: Excerpta Medica International Congress Series No. 391, 1977, pp. 58–64.Google Scholar
  7. 7.
    Winne D. Dependence of intestinal absorption in vivo on the unstirred layer. Naunyn Schmiedebergs Arch Pharmacol 1978;304:175–181.PubMedCrossRefGoogle Scholar
  8. 8.
    Suzuki A, Higuchi WI, Ho NFH. Theoretical model studies of drug absorption and transport in the gastrointestinal tract I. J Pharm Sci 1970;59:644–651.PubMedCrossRefGoogle Scholar
  9. 9.
    Suzuki A, Higuchi WI, Ho NFH. Theoretical model studies of drug absorption and transport in the gastrointestinal tract II. J Pharm Sci 1970;59:651–659.PubMedCrossRefGoogle Scholar
  10. 10.
    Winne D. Influence of blood flow in intestinal absorption of xenobiotics. Pharmacology 1980;21:1–15.PubMedCrossRefGoogle Scholar
  11. 11.
    Effeney DJ, Pond SM, Man-Wai L, Silber BM, Riegelman S. A technique to study hepatic and intestinal drug metabolism separately in the dog. J. Pharm Exp Ther 1982;221:507–511.Google Scholar
  12. 12.
    Back DJ, Breckenridge AM, Maciver M, Orme M, Purba HS, Rowe PH, Taylor I. The gut wall metabolism of ethinyloestradiol and its contribution to the pre-systemic metabolism of ethinyloestradiol in humans. Br J Clin Pharmacol 1982;13:325–330.PubMedGoogle Scholar
  13. 13.
    Back DJ, Bates M, Breckenridge AM, Ellis A, Hall JM, Maciver M, Orme M, Bowe PH. The in vitro metabolism of ethinyloestradiol mestranol and levonorgesterel by human jejunum mucosa. Br J Clin Pharmacol 1981;11:275–278.PubMedGoogle Scholar
  14. 14.
    Connolly ME, Davies DS, Dollery CT, Morgan CD, Paterson JW, Sandler M. Metabolism of isoprenaline in dog and man. Br J Pharmacol 1972;46:458–472.Google Scholar
  15. 15.
    Hartiala K. Metabolism of hormones, drugs and other substances by the gut. Physiol Rev 1973;53:496–534.PubMedGoogle Scholar
  16. 16.
    Barr WH, Riegelman S. Intestinal drug absorption and metabolism. II. Kinetic aspects of intestinal glucuronide conjugation. J Pharm Sci 1970;59:164–168.PubMedCrossRefGoogle Scholar
  17. 17.
    Del Villar E, Sanchez E, Tephly TR. Morphine metabolism II. Studies on morphine glucu-ronyl transferase activity in intestinal microsomes of rats. Drug Metab Dispos 1974;2:370–374.PubMedGoogle Scholar
  18. 18.
    George CF, Blackwell EW, Davies DS. Metabolism of isoprenaline in the intestine. J Pharm Pharmacol 1974;26:265–267.PubMedCrossRefGoogle Scholar
  19. 19.
    Hoensch HP, Hartmann F. The intestinal enzymatic bio-transformation system: Potential role in protection from colon cancer. Hepatogastroenterology 1981;28:221–228.PubMedGoogle Scholar
  20. 20.
    Pantuck EJ, Hsiao KC, Kuntzman R, Conney AH. Intestinal metabolism of phenacetin in the rat: effect of charcoal-broiled beef and rat chow. Science 1975;187:744–746.PubMedCrossRefGoogle Scholar
  21. 21.
    Goldman P, Peppercorn MA, Goldin BR. Drugs metabolized by intestinal microflora. In: Drug Interactions (Morselli, Cohen, Garattini, eds.). New York: Raven Press, 1974, pp. 91–102.Google Scholar
  22. 22.
    Blaschke TF. Protein binding and kinetics of drugs in liver diseases. Clin Pharmacokinet 1977;2:32–44.PubMedCrossRefGoogle Scholar
  23. 23.
    Branch RA, Herbert CM, Read AE. Determinants of serum antipyrine half-lives in patients with liver disease. Gut 1973;14:569–573.PubMedCrossRefGoogle Scholar
  24. 24.
    Andreasen PB, Ranek L. Liver failure and drug metabolism. Scand J Gastroenterol 1975; 10:293–297.PubMedGoogle Scholar
  25. 25.
    Caesar J, Shaldon S, Chiandussi L, Guevara L, Sherlock S. The use of indocyanine green in the measurement of hepatic blood flow and as a test of hepatic function. Clin Sci 1961;21:43–57.PubMedGoogle Scholar
  26. 26.
    Henderson JM, Hanna SS. Effective liver blood flow: Determination by galactose clearance. Can J Surg 1983;26:129–132.PubMedGoogle Scholar
  27. 27.
    Barr WH, Aceto T, Chung H, Shakur M. Dose-dependent drug metabolism during the absorptive phase. Rev Can Biol 1973;32:21–42.Google Scholar
  28. 28.
    Gibaldi M, Perrier D. Route of administration and drug disposition. Drug Metab Rev 1974;3:185–199.PubMedCrossRefGoogle Scholar
  29. 29.
    Murphy PJ, Sullivan HR. Stable isotopes in pharmacokinetic studies. Annu Rev Pharmacol Toxicol 1980;20:609–621.PubMedCrossRefGoogle Scholar
  30. 30.
    Eichelbaum M, Von Unruh G, Somogyi A. Application of stable labelled drugs in clinical pharmacokinetic investigations. Clin Pharmacokinet 1982;7:490–507.PubMedCrossRefGoogle Scholar
  31. 31.
    Nimmo WS. Drugs, diseases and altered gastric emptying. Clin Pharmacokinet 1976;1:189–203.PubMedCrossRefGoogle Scholar
  32. 32.
    Harris FC. Pyloric stenosis: Hold-up of enteric-coated aspirin tablets. Br J Surg 1973;60:979–981.PubMedCrossRefGoogle Scholar
  33. 33.
    Heading RC, Nimmo J, Prescott LF, Tothill P. The dependence of paracetamol absorption on the rate of gastric emptying. Br J Pharmacol 1973;47:415–421.PubMedGoogle Scholar
  34. 34.
    Nimmo J, Heading RC, Tothill P, Prescott LF. Pharmacological modifications of gastric emptying: Effects of propantheline and metoclopramide on paracetamol absorption. Br Med J 1973;1:587–589.PubMedCrossRefGoogle Scholar
  35. 35.
    Prescott LF. Gastrointestinal absorption of drugs. Med Clin NA 1974;58:907–916.Google Scholar
  36. 36.
    John AH, Jones AJ. Gastroenteritis causing failure of oral contraceptives. Br Med J 1975;3:207–208.PubMedCrossRefGoogle Scholar
  37. 37.
    Pottage A, Nimmo J, Prescott LF. The absorption of aspirin and paracetamol in patients with achlorhydria. J Pharmacol 1974;26:144–145.CrossRefGoogle Scholar
  38. 38.
    Davies JA, Holt JM. Absorption of cephalexin in diseased and aged subjects. J Antimicrob Chemother 1975;1 (supple):69–70.PubMedGoogle Scholar
  39. 39.
    Kramer PA, Chapron DJ, Benson J, Mercile SA. Tetracycline absorption in elderly patients with achlorhydria. Clin Pharmacol Ther 1978;23:467–472.PubMedGoogle Scholar
  40. 40.
    Venho VMK, Aukee S, Jussila J, Mattila MJ. Effect of gastric surgery on the gastrointestinal drug absorption in man. Scand J Gastroenterol 1975;10:43–47.PubMedGoogle Scholar
  41. 41.
    Antonioli JA, Schelling JL, Steininger E, Borel GA. Effect of gastrectomy and of an anticholinergic drug on the gastrointestinal absorption of a sulfonamide in man. Int Z Klin Pharmakol Ther Toxikol 1971;5:212–215.PubMedGoogle Scholar
  42. 42.
    Ochs H, Bodem G, Kodrat G, Savic B, Baur MP. Biologische Verfugbarkeit von Digoxin bei patienten mit und ohne magenresektion nach Billroth II. Dtsch Med Wochenschr 1975;100:2430–2434.PubMedCrossRefGoogle Scholar
  43. 43.
    Hall WH, Doherty JE. Tritiated digoxin XXII. Absorption and excretion in malabsorption Syndromes. Am J Med 1974;56:437–442.PubMedCrossRefGoogle Scholar
  44. 44.
    Gerson CD, Lowe EH, Lindenbaum J. Bioavailability of digoxin tablets in patients with gastrointestinal dysfunction. Am J Med 1980;69:43–49.PubMedCrossRefGoogle Scholar
  45. 45.
    Jusko WJ et al. Digoxin absorption from tablets and elixir. The effect of radiation-induced malabsorption. J Am Med Assoc 1974;230:1554–1555.CrossRefGoogle Scholar
  46. 46.
    Sandle Gl, Ward A, Rawlins MD, Record CO. Propranolol absorption in untreated coeliac disease. Clin Sci 1982;63:81–85.PubMedGoogle Scholar
  47. 47.
    Johansson EDB, Krai JG. Oral contraceptives after intestinal bypass operations. J Am Med Assoc 1976;236:2847.Google Scholar
  48. 48.
    Backman L, Beermann B, Groschinsky-Grind M, Hallberg D. Malabsorption of hydrochlorothiazide following intestinal shunt surgery. Clin Pharmacokinet 1979;4:63–68.PubMedCrossRefGoogle Scholar
  49. 49.
    Kennedy MC, Wade DN. Phenytoin absorption in patients with ileojejunal bypass. Br J Clin Pharmacol 1979;7:515–518.PubMedGoogle Scholar
  50. 50.
    Sokol GH, Greenblatt DJ, Lloyd BL, Georgotas A, Allen MD, Harmatz JS, Smith TW, Shader RI. Effect of abdominal radiation therapy on drug absorption in humans. J Clin Pharmacol 1978;18:388–396.PubMedGoogle Scholar
  51. 51.
    Parsons RL. Drug absorption in gastrointestinal disease with particular reference to malabsorption syndromes. Clin Pharmacokinet 1977:2:45–60.PubMedCrossRefGoogle Scholar
  52. 52.
    Parsons RL, Kaye CM, Raymond K, Trounce JR, Turner P. Absorption of propranolol and practolol in coeliac disease. Gut 1976;17:139–143.PubMedCrossRefGoogle Scholar
  53. 53.
    Schneider RE, Babb J, Bishop H, Mitchard M, Hoare AM, Hawkins CF. Plasma levels of propranolol in treated patients with coeliac disease and patients with Crohn’s disease. Br Med J 1976;2:794–795.PubMedCrossRefGoogle Scholar
  54. 54.
    Melander A, Kahlmeter G, Kamme C, Ursing B. Bioavailability of metronidazole in fasting and non-fasting healthy subjects and in patients with Crohn’s disease. Eur J Clin Pharmacol 1977;12:69–72.PubMedCrossRefGoogle Scholar
  55. 55.
    Bergan T, Bjerke Pern, Fausa O. Pharmacokinetics of metronidazole in patients with enteric disease compared to normal volunteers. Chemotherapy 1981;27:233–238.PubMedCrossRefGoogle Scholar
  56. 56.
    Shaffer JA, Williams SE, Turnberg LA, Houston JB, Rowland M. Absorption of prednisolone in patients with Crohn’s disease. Gut 1983;24:182–186.PubMedCrossRefGoogle Scholar
  57. 57.
    Milsap RL, George DE, Szefler SJ, Murray KA, Lebenthal E, Jusko WJ. Effects of inflammatory bowel disease on absorption and disposition of prednisolone. Dig Dis Sci 1983;28:161–168.PubMedCrossRefGoogle Scholar
  58. 58.
    Kitis G, Lucas ML, Schneider RE, Bishop H, Sargent A, Blair JA, Allan RN. Jejunal acid microclimate and its effects on absorption of folic acid and propranolol. Gut 1983;24:A438.CrossRefGoogle Scholar
  59. 59.
    Parsons RL, Kaye CM, Raymond K. Pharmacokinetics of salicylate and indomethacin in coeliac disease. Eur J Clin Pharmacol 1977;11:473–477.PubMedCrossRefGoogle Scholar
  60. 60.
    Parsons RL, Paddock GM. Absorption of two antibacterial drugs, cephalexin and co-trimoxazole in malabsorption syndromes. J Antimicrob Chemother 1975;1:(Suppl):59–67.PubMedCrossRefGoogle Scholar
  61. 61.
    Parsons RL, Paddock GM, Hossack GM, Hailey DM. Antibiotic absorption in Crohn’s disease. In: Chemotherapy, Vol 4, Pharmacology of Antibiotics (Williams, Gebbes, eds). New York: Plenum Press, 1976, pp. 219–229.Google Scholar
  62. 62.
    Holt S, Heading RC, Clements JA, Tothill P, Prescott LF. Acetaminophen absorption and metabolism in celiac disease and Crohn’s disease. Clin Pharmacol Ther 1981;30:232–238.PubMedCrossRefGoogle Scholar
  63. 63.
    Wilkinson GR, Schenker S. Drug disposition and liver disease. Drug Metab Rev 1976;4:139–175.CrossRefGoogle Scholar
  64. 64.
    Wood AJJ, Kornhauser DM, Wilkinson GR, Shand DG, Branch RA. The influence of cirrhosis on steady-state blood concentrations of unbound propranolol after oral administration. Clin Pharmacokinet 1978;3:478–487.PubMedCrossRefGoogle Scholar
  65. 65.
    Regardh C-G, Jordo L, Ervik M, Lundborg P, Olsson R, Ronn O. Pharmacokinetics of metoprolol in patients with hepatic cirrhosis. Clin Pharmacokinet 1981;6:375–388.PubMedCrossRefGoogle Scholar
  66. 66.
    Neal EA, Meffin PJ, Gregory PB, Blaschke TF. Enhanced bioavailability and decreased clearance of analgesics in patients with cirrhosis. Gastroenterology 1979;77:96–102.PubMedGoogle Scholar
  67. 67.
    Kleinbloesem, Van Harten J, Wilson JPH, Danhof M, Van Brummelen P, Breimer DD. Nifedipine: Kinetics and hemodymanic effects in patients with liver cirrhosis after intravenous and oral administration. Clin Pharmacol Ther 1986;40:21–28.PubMedCrossRefGoogle Scholar
  68. 68.
    Adjepon-Yamoah KK, Nimmo J, Prescott LF. Gross impairment of hepatic drug metabolism in a patient with chronic liver disease. Br Med J 1974;4:387–388.PubMedCrossRefGoogle Scholar
  69. 69.
    Thomson PD, Melmon KL, Richardson JA, Cohn K, Steinbrunn W, Cuolihee R, Rowland M. Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans. Ann Intern Med 1973;78:499–508.PubMedGoogle Scholar
  70. 70.
    Williams RL, Blaschke TF, Meffin PJ, Melmon KL, Rowland M. Influence of viral hepatitis on the disposition of two compounds with high hepatic clearance: Lidocaine and indocyanine green. Clin Pharmacol Ther 1976;20:290–299.PubMedGoogle Scholar
  71. 71.
    Piafsky KM, Sitar DS, Rangno RE, Ogilvie RI. Theophylline disposition in patients with hepatic cirrhosis. N Engl J Med 1977;296:1495–1497.PubMedCrossRefGoogle Scholar
  72. 72.
    Klotz U, Arant GR, Hoyumpa A, Schenker S, Wilkinson GR. The effects of age and liver disease on the disposition and elimination of diazepam in adult man. J Clin Invest 1975;55:347–359.PubMedCrossRefGoogle Scholar
  73. 73.
    Greenblatt DJ, Harmatz JJ, Shader RI. Factors influencing diazepam pharmacokinetics: Age, sex, and liver disease. Int J Clin Pharmacol Biopharm 1978;16:177–179.PubMedGoogle Scholar
  74. 74.
    Shull HJ, Wilkinson GR, Johnson R, Schenker S. Normal disposition of oxazepam in acute viral hepatitis and cirrhosis. Ann Intern Med 1976;84:420–425.PubMedGoogle Scholar
  75. 75.
    Kraus JW, Marshall JP, Johnson R, Wilkinson GR, Schenker S. Lorazepam elimination in liver disease. Gastroenterology 1911 (abstract);73:1228.Google Scholar
  76. 76.
    Witassek F, Bircher J, Huguenin P, Preisig R. Abnormal glucuronidation of zomepirac in patients with cirrhosis of the liver. Hepatology 1983:3:415–422.PubMedCrossRefGoogle Scholar
  77. 77.
    Thiessen JJ, Sellers EM, Denbeigh P, Dolman L. Plasma protein binding of diazapam and tolbutamide in chronic alcoholics. J Clin Pharmacol 1976;16:345–351.PubMedGoogle Scholar
  78. 78.
    Schenker S, Hoyumpa AM Jr, Wilkinson GR. The effect of parenchymal liver disease on the disposition and elimination of sedatives and analgesics. Med Clin NA 1975;59:877–896.Google Scholar
  79. 79.
    Anon. Safe prescribing in liver disease. Br Med J 1973;2:193–194.CrossRefGoogle Scholar
  80. 80.
    Levy G, Tsuchiya T. Effect of activated charcoal on aspirin absorption in man. Part I. Clin Pharmacol Ther 1972;13:317–322.PubMedGoogle Scholar
  81. 81.
    Neuvonen PJ, Elonen E. Effect of activated charcoal on absorption and elimination of phenobarbitone, carbamazepine and phenylbutazone in man. Eur J Clin Pharmacol 1980;17:51–57.PubMedCrossRefGoogle Scholar
  82. 82.
    Northcott RC, Stiel JN, Hollifield JW, Stant EG Jr. The influence of cholestyramine on thyroxine absorption. J Am Med Assoc 1969;208:1857–1861.CrossRefGoogle Scholar
  83. 83.
    Robinson DS, Benjamin DM, McCormack JJ. Interaction of warfarin and nonsystemic gastrointestinal drugs. Clin Pharmacol Ther 1971;12:491–495.PubMedGoogle Scholar
  84. 84.
    Vander Meer JWH, Scheijgronel HW, Heykants J, Van Cutsem J, Brugmans J. The influence of gastric acidity on the bio-availability of ketoconazole. J Antimicrob Chemo 1980;6:552–554.CrossRefGoogle Scholar
  85. 85.
    Hurwitz A. Antacid therapy and drug kinetics. Clin Pharmacokinet 1977;2:269–280.PubMedCrossRefGoogle Scholar
  86. 86.
    Prescott LF. Gastric emptying and drug absorption. Br J Clin Pharm 1974;1:189–190.Google Scholar
  87. 87.
    Steinberg WM, Lewis JH. Mylanta II inhibits the absorption of Cimetidine. Gastroenterology 1980;78:1269.Google Scholar
  88. 88.
    Steinberg WM, Lewis JH, Katz DM. Antacids inhibit absorption of Cimetidine. N Engl J Med 1982;307:400–404.PubMedCrossRefGoogle Scholar
  89. 89.
    Gugler R, Brand M, Somogyi A. Impaired Cimetidine absorption due to antacids and metoclopramide. Eur J Clin Pharmacol 1981;20:225–228.PubMedCrossRefGoogle Scholar
  90. 90.
    Russell WL, Lopez LM, Normann SA, Doering PL, Guild RT. Effect of antacids on predicted steady-state Cimetidine concentrations. Dig Dis Sci 1984;29:385–389.PubMedCrossRefGoogle Scholar
  91. 91.
    Mahachai V, Jamali F, Thomson ABR. Effect of combination of antacids and Cimetidine on 24-hour intragastric acidity in patients with asymptomatic duodenal ulcer. Clin Therapeut 1984;6:808–823.Google Scholar
  92. 92.
    Harcourt RS, Hamburger M. The effect of magnesium sulfate in lowering tetracycline blood levels. J Lab Clin Med 1957;50:464–468.PubMedGoogle Scholar
  93. 93.
    Hurwitz A. Antacid therapy and drug kinetics. Clin Pharmacokinet 1977;2:269–280.PubMedCrossRefGoogle Scholar
  94. 94.
    Manninen V, Apajalahti A, Melin J, Karesoja M. Altered absorption of digoxin in patients given propantheline and metoclopramide. Lancet 1973;1:398–400.PubMedCrossRefGoogle Scholar
  95. 95.
    Levy G, Gibaldi M, Procknal JA. Effect of an anticholinergic agent on riboflavin absorption in man. J Pharm Sci 1972;61:798–799.PubMedCrossRefGoogle Scholar
  96. 96.
    Gibbons DO, Lant AF. Effects of intravenous and oral propantheline and metoclopramide on ethanol absorption. Clin Pharmacol Ther 1975;17:578–584.PubMedGoogle Scholar
  97. 97.
    Nimmo J. The influence of metoclopramide on drug absorption. Postgrad Med J 1973;49(Suppl) 25–28.PubMedGoogle Scholar
  98. 98.
    Gothoni G, Pentikainen P, Vapaatalo HI, Hackman R, Afbjorksten K. Absorption of antibiotics: Influence of metoclopramide and atropine on serum levels of pivampicillin and tetracycline. Ann Clin Res 1972;4:228–232.PubMedGoogle Scholar
  99. 99.
    Charles BG, Renshaw PJ, Kay JJ, Ravenscroft PJ. Effect of metoclopramide on the bioavailability of long-acting propranolol. Br J Clin Pharmacol 1981;11:517–518.PubMedGoogle Scholar
  100. 100.
    Somogyi A, Gugler R. Drug interactions with Cimetidine. Clin Pharmacokinet 1982;7:23–41.PubMedCrossRefGoogle Scholar
  101. 101.
    Jamali F, Mahachai V, Reilly P, Thomson ABR. Lack of pharmacokinetic interaction between Cimetidine and pirenzepine. Clin Pharmacol Ther 1985;38:325–330.PubMedCrossRefGoogle Scholar
  102. 102.
    Alvan G, Piafsky k, Lind M, Von Bahr C. Effect of pentobarbital on the disposition of alprenolol. Clin Pharmacol Ther 1977;22:316–321.PubMedGoogle Scholar
  103. 103.
    Data JL, Wilkinson GR, Nies AS. Interaction of quinidine with anticonvulsant drugs. N Engl J Med 1976;294:699–702.PubMedCrossRefGoogle Scholar
  104. 104.
    Neuvonen PJ, Penttila O. Interaction between doxycycline and barbiturates. Br Med J 1974;1:535–536.PubMedCrossRefGoogle Scholar
  105. 105.
    Aitio M-L, Mansury L, Tala E, Haataja M, Aitio A. The effect of enzyme induction on the metabolism of disopyramide in man. Br J Clin Pharmacol 1981;11:279–285.PubMedGoogle Scholar
  106. 106.
    O’Reilly RA. Interaction of sodium warfarin and rifampin. Studies in man. Ann Intern Med 1974;81:337–340.PubMedGoogle Scholar
  107. 107.
    Syvalahti EKG, Pihlajamaki KK, Iisalo EJ. Rifampicin and drug metabolism. Lancet 1974;2:232–233.PubMedCrossRefGoogle Scholar
  108. 108.
    Ahmad D, Mathur P, Ahuja S, Henderson R, Carruthers G. Rifampicin-quinidine interaction. Br J Dis Chest 1979;73:409–411.PubMedCrossRefGoogle Scholar
  109. 109.
    Bennett PN, John VA, Witmarsh VB. Effect of rifampicin on metoprolol and antipyrine kinetics. Br J Clin Pharmacol 1982;13:387–391.PubMedGoogle Scholar
  110. 110.
    Carrum G, Egan JM, Abernethy DR. Diltiazem treatment impairs hepatic drug oxidation: Studies of antipyrine. Clin Pharmacol Ther 1986;40:140–143.PubMedCrossRefGoogle Scholar
  111. 111.
    Speek KV, Patwardhan RV, Avant GR, Mitchell MC, Schenker S. Inhibition of microsomal drug metabolism by histamine H2-receptor antagonists studied in vivo and in vitro in rodents. Gastroenterology 1982;82:89–96.Google Scholar
  112. 112.
    Klotz U, Anttila V, Reimann I. Cimetidine/diazepam interaction. Lancet 1979;2:699.PubMedCrossRefGoogle Scholar
  113. 113.
    Desmond PV, Patwardhan RV, Schenker S, Speek KV Jr. Cimetidine impairs elimination of chlordiazepoxide (Librium) in man. Ann Intern Med 1980;93:266–268.PubMedGoogle Scholar
  114. 114.
    Feely J, Wilkinson GR, Wood AJJ. Reduction of liver blood flow and propranolol metabolism by Cimetidine. N Engl J Med 1981;304:692.PubMedCrossRefGoogle Scholar
  115. 115.
    Somogyi A, Gugler R. Drug interactions with Cimetidine. Clin Pharmacokinet 1982;7:23–41.PubMedCrossRefGoogle Scholar
  116. 116.
    Klotz U, Reimann I. Influence of Cimetidine on the pharmacokinetics of desmethyldiazepam and oxazepam. Eur J Clin Pharmacol 1980;18:517–520.PubMedCrossRefGoogle Scholar
  117. 117.
    Reimann IW, Klotz U, Siems B, Frolich JC. Cimetidine increases steady state plasma levels of propranolol. Br J Clin Pharmacol 1981;12:785–790.PubMedGoogle Scholar
  118. 118.
    Reimann IW, Klotz U, Froelich JC. Effects of Cimetidine and ranitidine on steady state propranolol kinetics and dynamics. Clin Pharmacol Ther 1982;32:749–757.PubMedCrossRefGoogle Scholar
  119. 119.
    Heagerty AM, Donovan MA, Castleleden CM, Pohl JF, Patel L. The influence of histamine (H2) antagonists on propranolol pharmacokinetics. Int J Clin Pharmacol Res 1982;2:203–205.Google Scholar
  120. 120.
    Feely J, Guy E. Lack of effect of ranitidine on the disposition of lignocaine. Br J Pharmacol 1983;15:378–379.Google Scholar
  121. 121.
    Serlin MJ, Sibeon RG, Breckenridge AM. Lack of effect of ranitidine on warfarin action. Br J Clin Pharmacol 1981;12:791–794.PubMedGoogle Scholar
  122. 122.
    Nies AS, Evans GH, Shand DG. Regional hemodynamic effects of beta-adrenergic blockade with propranolol in the unanesthetized primate. Am Heart J 1973;85:97–102.PubMedCrossRefGoogle Scholar
  123. 123.
    Ochs HR, Carstens G, Greenblatt DJ. Reduction in lidocaine clearance during continuous infusion and by coadministration of propranolol. N Engl J Med 1980;303:373–377.PubMedCrossRefGoogle Scholar
  124. 124.
    White RJ, Chamberlain DA, Howard M, Smith TW. Plasma concentrations of digoxin after oral administration in the fasting and postprandial state. Br Med J 1971;1:380.PubMedCrossRefGoogle Scholar
  125. 125.
    Jaffe JM, Colaizzi JL, Barry H. Effects of dietary components on GI absorption of acetaminophen tablets in man. J Pharm Sci 1971;60:1646–1650.PubMedCrossRefGoogle Scholar
  126. 126.
    MacDonald H, Place VA, Falk H, Darken MA. Effect of food on absorption of sulfonamides in man. Chemotherapy 1967;12:282–285.PubMedCrossRefGoogle Scholar
  127. 127.
    Kirby WMM, Roberts CE, Bardick RE. Comparison of two new tetracyclines with tetracycline and demethylchlortetracycline. Antimicrob Agents Chemother, October 31-November 2, 1961;286–292.Google Scholar
  128. 128.
    Klein JO, Finland M. The new penicillins. N Engl J Med 1963;269:1019–1025.PubMedCrossRefGoogle Scholar
  129. 129.
    Welling PG, Huang H, Koch PA, Craig WA, Madsen PO. Bioavailability of ampicillin and amoxicillin in fasted and nonfasted subjects. J Pharm Sci 1977;66:549–552.PubMedCrossRefGoogle Scholar
  130. 130.
    Siegler DI, Bryant M, Burley DM, Citron KM. Effect of meals on rifampicin absorption. Lancet 1974;2:197–198.PubMedCrossRefGoogle Scholar
  131. 131.
    Welling PG, Koch PA, Lau CC, Craig WA. Bioavailability of tetracycline and doxycycline in fasted and nonfasted subjects. Antimicrob Agents Chemother 1977;11:462–469.PubMedGoogle Scholar
  132. 132.
    Rosenblatt JE, Barrett JE, Brodie JL, Kirby WM. Comparison of in vitro activity and clinical pharmacology of doxycycline and other tetracylines. Antimicrob Agents Chemother November 26–28, 1966;134–141.Google Scholar
  133. 133.
    Overdiek HWPM, Merkus FWHM. Influence of food on the bioavailability of spironolactone. Clin Pharmacol Ther 1986;40:531–536.PubMedCrossRefGoogle Scholar
  134. 134.
    Melander A, Danielson K, Schersten B, Wahlin E. Enhancement of the bioavailability of propranolol and metoprolol by food. Clin Pharmacol Ther 1977;22:108–112.PubMedGoogle Scholar
  135. 135.
    Melander A, McLean A. Influence of food intake on presystemic clearance of drugs. Clin Pharmacokinet 1983;8:286–297.PubMedCrossRefGoogle Scholar
  136. 136.
    Liedholm H, Melander A. Concomitant food intake can increase the bioavailability of propranolol by transient inhibition of its presystemic primary conjugation. Clin Pharmacol Ther 1986;40:29–36.PubMedCrossRefGoogle Scholar
  137. 137.
    Basu TK. Effect of protein malnutrition and ascorbic acid levels on drug metabolism. Can J Physiol Pharmacol 1983;61:295–301.PubMedCrossRefGoogle Scholar
  138. 138.
    Pantuck EJ, Pantuck CB, Garland WA, Min BH, Wattenberg LW, Anderson KE, Kappas A, Conney AH. Stimulatory effect of brussel sprouts and cabbage on human drug metabolism. Clin Pharm Ther 1979;25:88–95.Google Scholar
  139. 139.
    Castleden CM, Volans CN, Raymond K. The effect of aging on drug absorption from the gut. Age Aging 1977;6:138–143.CrossRefGoogle Scholar
  140. 140.
    Massoud N. Pharmacokinetic considerations in geriatric patients. In: Pharmacokinetic Basis for Drug Treatment (Benet LZ, Massoud N, Gambertoglio JG, eds). New York: Raven Press, 1984, pp. 283–310.Google Scholar
  141. 141.
    Greenblatt DJ, Sellers EM, Shader RT. Drug disposition in old age. N Engl J Med 1982;306:1081–1088.PubMedCrossRefGoogle Scholar
  142. 142.
    Schmucker DL. Aging and drug disposition: An update. Pharmacol Rev 1985;37:133–148.PubMedGoogle Scholar
  143. 143.
    Triggs EJ, Nation RL. Pharmacokinetics in the aged: A review. J Pharmacokinet Biopharm 1975;3:387–418.PubMedCrossRefGoogle Scholar
  144. 144.
    Bach B, Hansen JM, Kampmann JP, Rasmussen SN, Skovsted L. Disposition of antipyrine and phenytoin correlated with age and liver volume in man. Clin Pharmacokinet 1981;6:389–396.PubMedCrossRefGoogle Scholar
  145. 145.
    Farah F, Taylor W, Rawlins MD, James D. Hepatic drug acetylation and oxidation: effects of aging in man. Br Med J 1977;2:155–156.PubMedCrossRefGoogle Scholar
  146. 146.
    Vestal RE, Norris AH, Tobin JD, Cohen BH, Shock NW, Andres R. Antipyrine metabolism in man: Influence of age, alcohol, caffeine and smoking. Clin Pharmacol Ther 1975; 18:425–432.PubMedGoogle Scholar
  147. 147.
    Smithard DJ, Langman MJS. Drug metabolism in the elderly. Br Med J 1977;2:520–521.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1989

Authors and Affiliations

  • Varocha Mahachai
    • 1
  1. 1.Division of Gastroenterology, Department of MedicineUniversity of AlbertaEdmontonCanada

Personalised recommendations